|
Post by BD on Sept 6, 2014 18:33:45 GMT -5
Good work, thank you paradigm. I was pretty rushed this morning and just ran out of time to figure it out. I knew my result didn't make sense after reading the Wiki analysis.
|
|
|
Post by babaoriley on Sept 6, 2014 19:35:26 GMT -5
Baba, Does that mean I get a goat or get to learn how this makes us become better traders? jpg, the moral of that riddle is very applicable to trading stocks - what you think initially is often wrong, and the more sure you are about something, the more likely it is you're incorrect, so do the opposite. More generally, the riddle tells you things are often not what they seem! Remember that next time you plan a trade! LOL!
|
|
|
Post by babaoriley on Sept 6, 2014 19:37:45 GMT -5
Q2U, let me put your MNKD relevant post back up to the top.
|
|
|
Post by jpg on Sept 6, 2014 21:58:09 GMT -5
Baba, Does that mean I get a goat or get to learn how this makes us become better traders? jpg, the moral of that riddle is very applicable to trading stocks - what you think initially is often wrong, and the more sure you are about something, the more likely it is you're incorrect, so do the opposite. More generally, the riddle tells you things are often not what they seem! Remember that next time you plan a trade! LOL! I hope you aren't suggesting our collective optimism in Mannkind isn't misplaced? Would you be a secret spy for' the pessimist board' aka 'the other board'? You do realize some have been banned for lesser offenses on other boards? The slightly different conclusion I come up with is don't do what you aren't good at... JPG
|
|
|
Post by jpg on Sept 6, 2014 22:41:33 GMT -5
Sanofi will probably be very careful about advertising or publisizing what they will do and when. They will make stuff public when and onlyvwhen it suits their purpose. For infrmation hungry retail invetors like us going from a baby biotech to a BP can often be a traumatic experience. Sanofi is going to. Be much less. Concerned about the needs of retail Sanofi investors. Imagine how little they will care about MNKD investors... JPG
|
|
|
Post by babaoriley on Sept 7, 2014 19:44:50 GMT -5
Gosh, jpg, I hope having Sanofi on our side does not turn MNKD into a black hole, at least when it comes to the marketing efforts for Afrezza. Hoping Al has some decent leeway in discussing current topics, and perhaps we'll get some insight into that leeway at this next presentation this Tuesday. At the same time, I can certainly see Sanofi keeping quiet, what is material to them is a whole different world than what is material to MNKD.
O/T - only for those who like riddles - I've posted one "On the Lighter Side" board, under the name, "Easy Street."
|
|
|
Post by jpg on Sept 7, 2014 20:33:12 GMT -5
Baba, An interesting breakdown of Sanofi sales by product, region, category etc. en.sanofi.com/investors/key_facts_figures/net_sales/net_sales.aspxWhen Sanofi discusses results, guidance etc. we should not be shocked if Afrezza doesn't occupy a significant part of the discussion. Sanofi had sales of almost 33 billion last year. Interestingly only 10.4 billion in the US and only 2.5 billion in Japan. Partner biotechs are usually the ones that give 'color' on what the BP is doing with their product. This can often be a difficult balancing act for all. I agree it will he interesting to see MNKDs leeway on Afrezza in the next few public engagements they will attend. it will also be interesting to see if there is a 'full steam ahead' mentality on Texhnosphere and if they announce or hint at near term partnerships. JPG PS: you burnt me out intellectually with your riddle. It will take me months to recover.
|
|